News Sentiment

CGON sentiment intelligence

CG Oncology, Inc. Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 75.24 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+6.9% over one week, +26.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

[144] CG Oncology, Inc. SEC Filing

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 6.9% Price confirming higher
Trend fit Trend active 26.3% over four weeks
Fair value 90.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 8
TradingView 6
Quiver Quantitative 3
Moomoo 2
Investing.com Canada 2
Investing.com 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 19
Guidance 2
Regulatory and legal 1
Balance sheet 1
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Stock Titan Direct company coverage

[144] CG Oncology, Inc. SEC Filing

This SEC filing for CG Oncology, Inc. (CGON) outlines a Form 144 Notice of Proposed Sale of Securities. The filing details the sale of 52,438 shares of common stock with an aggregate market value of $3,816,007.65, acquired through a stock option exercise, by an insider on July 15

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:43
Source
Stock Titan
Stock Titan Direct company coverage

CG Oncology (CGON) director exercises options, sells 24,165 shares

CG Oncology, Inc. director James Mulay exercised options to acquire 24,165 shares of common stock at $26.63 per share and subsequently sold all those shares in an open-market transaction at a weighted average price of $75.16 per share. These sales were conducted under a Rule 10b5

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 19:51
Source
Stock Titan
Simply Wall Street Direct company coverage

CG Oncology (CGON) In Focus Following Early Trial Results And BLA Timing Questions On Value

CG Oncology is gaining attention after positive early Phase II trial data for its bladder cancer treatment and a clearer timeline for its Biologics License Application (BLA). The stock has seen significant returns, yet its valuation presents a mixed picture: undervalued compared

Tone
Positive 75/100
Event
Earnings
Published
13 Jul 2026 22:40
Source
Simply Wall Street
TradingView Direct company coverage

CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CG Oncology (CGON) shares have risen 12% in the past three months, driven by investor optimism for its lead bladder cancer therapy, cretostimogene grenadenorepvec, accelerating regulatory progress, and a strong balance sheet. The company is making steady progress towards a BLA su

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 12:40
Source
TradingView
Investing.com South Africa Direct company coverage

Form 144 CG Oncology For: 10 July By Investing.com

This article from Investing.com reports on a Form 144 filing for CG Oncology dated July 10. Such filings typically indicate an insider's intent to sell restricted stock. The brief article provides the basic announcement without further details or analysis, reflecting a standard n

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 09:39
Source
Investing.com South Africa
Moomoo Direct company coverage

Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating

Truist Financial has reiterated its Buy rating on CG Oncology (CGON.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.

Tone
Positive 69/100
Event
Guidance
Published
11 Jul 2026 01:40
Source
Moomoo
Investing.com Canada Direct company coverage

Form DEF 14A CG Oncology Inc For: 10 July By Investing.com

This article from Investing.com announces the filing of Form DEF 14A by CG Oncology Inc. for July 10th. The brief notice directs readers to view the filing, which is a standard SEC document related to proxy statements. The article also mentions CGON's stock performance.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:10
Source
Investing.com Canada
Stock Titan Direct company coverage

Cognition Therapeutics (NASDAQ: CGON) insider plans sale of 20,237 shares

Cognition Therapeutics (NASDAQ: CGON) insider James Mulay has filed a Form 144 to potentially sell 20,237 common shares through Morgan Stanley Smith Barney, valued at $1,483,776.84 as of July 10, 2026. These shares are related to the exercise of stock options for cash. The filing

Tone
Negative 40/100
Event
Balance sheet
Published
10 Jul 2026 21:10
Source
Stock Titan
Finviz Direct company coverage

CGON - Cg Oncology Inc Options

This page provides comprehensive financial data and performance metrics for CGON (Cg Oncology Inc Options). It includes the stock's last close price, dollar and percentage change, various financial ratios, earnings per share details, insider and institutional ownership, and short

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 23:39
Source
Finviz
Quiver Quantitative Direct company coverage

CG Oncology Stock (CGON) Opinions on Director's Massive Share Purchase

Social media discussions are focusing on a CG Oncology (CGON) director's recent acquisition of nearly $25 million in shares, signaling strong internal confidence in the company's clinical pipeline for bladder cancer immunotherapy. This purchase, combined with the company's positi

Tone
Positive 74/100
Event
Deals and strategy
Published
02 Jul 2026 18:40
Source
Quiver Quantitative
Stock Titan Direct company coverage

Insider sale notice: CGON (NASDAQ: CGON) 3,928 shares via exercise

CG Oncology, Inc. (NASDAQ: CGON) filed a Rule 144 notice indicating an intended resale of 3,928 shares related to an exercise of stock options on July 1, 2026, with Morgan Stanley Smith Barney LLC handling the transaction. The filing also discloses prior 10b5-1 sales by James Mul

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:10
Source
Stock Titan
Investing.com Direct company coverage

CG Oncology stock hits all-time high at 75.79 USD

CG Oncology Inc.'s stock recently hit an all-time high of $75.79, and currently trades just below its 52-week high, reflecting a significant 183.58% increase over the past year. Despite this surge, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Va

Tone
Positive 73/100
Event
Market update
Published
30 Jun 2026 14:41
Source
Investing.com
Investing.com Canada Direct company coverage

Form PRE 14A CG Oncology Inc For: 29 June By Investing.com

This article reports a Form PRE 14A filing by CG Oncology Inc. for June 29, 2026. The piece is brief, noting the filing and linking it to the company's stock symbol CGON, which experienced a 2.46% increase. The content primarily focuses on financial market data and general news u

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 22:40
Source
Investing.com Canada
Stock Titan Direct company coverage

CG Oncology (CGON) director-affiliated fund adds 371K shares

Seven Fleet Partners LP, an entity linked to CG Oncology director Brian Guan-Chyun Liu, acquired 371,085 shares of CGON common stock for $24.81 million at a price of $66.87 per share on June 25, 2026. This open-market purchase increased Five Fleet Partners LP's indirect holdings

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 21:40
Source
Stock Titan
www.marketscreener.com Direct company coverage

CG Oncology Insider Bought Shares Worth $24,814,454, According to a Recent SEC Filing

An insider at CG Oncology, Inc. (CGON) recently purchased shares valued at $24,814,454, according to a recent SEC filing. The biopharmaceutical company is focused on developing bladder-sparing therapeutics for bladder cancer, with its product candidate cretostimogene grenadenorep

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 10:39
Source
www.marketscreener.com
TradingView Direct company coverage

CG Oncology, Inc. Actuals & Estimates (NASDAQ:CGON)

This article provides an overview of CG Oncology, Inc. (NASDAQ:CGON) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue for past and upcoming quarters, as well as ma

Tone
Positive 60/100
Event
Earnings
Published
26 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

CG Oncology, Inc. Actuals & Estimates (BOATS:CGON)

This article provides an overview of CG Oncology, Inc. (CGON) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It details the company's stock forecast, historical prices, upcoming earnings report, and recent financial perform

Tone
Negative 41/100
Event
Earnings
Published
26 Jun 2026 14:41
Source
TradingView
TradingView Direct company coverage

CGON Forecast — Price Target — Prediction for 2027

This article provides a forecast for CG Oncology, Inc. (CGON) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial data like EPS, revenue, and net income, and answers frequently asked questions about the company's stock,

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 05:41
Source
TradingView
Stock Titan Direct company coverage

CG Oncology (NASDAQ: CGON) director sells 5,000 shares, exercises options

CG Oncology director Leonard E. Post sold 5,000 shares of common stock at $70.00 per share on June 24, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. On the same date, he exercised a director stock option to acquire 5,000 common shares at an exercise price of $0.60 per

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Form 144: 5,000-share exercise sale reports for CGON (CGON)

A Form 144 filing by Morgan Stanley Smith Barney LLC reports the sale of 5,000 shares of CG Oncology, Inc. common stock, resulting from an option exercise on June 24, 2026. The filing also discloses previous 10b5-1 sales by Leonard Post, totaling 6,000 shares for gross proceeds o

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

CG Oncology (NASDAQ: CGON) director exercises options and sells 5,000 shares

CG Oncology director Leonard E. Post exercised options to acquire 5,000 shares at $0.60 per share and subsequently sold these 5,000 shares at $65.00 in an open-market transaction on June 22, 2026. The sale was conducted under a Rule 10b5-1 trading plan adopted on March 5, 2026. F

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:41
Source
Stock Titan